Stealth Bio may be rethinking its low-profile approach to an IPO.
The company just launched its initial offering, pricing 6.5 million shares for $MITO at $12 — the low end of the range — and raising $78 million for its work on a pipeline of drugs focused on mitochondrial diseases after applying for an IPO in Hong Kong that never materialized.
Morningside veteran Reenie McCarthy — a lawyer by training — is in charge of the enterprise while Mark Bamberger, a former cardio and metabolic research chief at Pfizer, is CSO.
The team at Stealth may have remained under the radar, but they’ve burned through $400 million working on new therapies related to mitochondrial dysfunction. Mitochondria are the powerhouses of the cell, turning fuel into energy. And when that goes wrong, it can spur a host of diseases, running from rare genetic conditions to broad issues related to aging.
The biotech has a Phase III program all lined up and ready to read out later in the year, looking for promising data on elamipretide on primary mitochondrial myopathy. The biotech has 4 clinical programs underway, with the earliest targeting dry, age-related macular degeneration.
Morningside Ventures owned the lion’s share of the equity going into the IPO, with 95.3% of the stock.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription